Table 2

Clinical and laboratory features of patients with Guillain-Barré syndrome (GBS) associated with SARS-CoV-2 infection

Number (%)
Total number of patients42
Neurological features
 Confusion and agitation1 (2.4)
 Ophthamoparesis7 (16.7)
 Facial palsy16 (38.1) bilateral 13/16 (81.2)
 Bulbar palsy11 (26.2)
 Four limbs weakness27 (64.3)
 Weakness limited to LLs5 (11.9)
 Hypoareflexia34 (80.9)
 Sensory disturbances28 (66.7)
 Ataxia10 (23.8)
 Dysautonomia8 (19.0)
Clinical classification
 Classic GBS30 (71.4)
 Paraparetic2 (4.8)
 Facial diplegia with/without paraesthesia3 (7.1)
 Cranial polyneuritis2 (4.8)
 Miller Fisher syndrome3 (7.1)
 Acute ataxic neuropathy2 (4.8)
Electrodiagnosis
 Not done6 (14.3)
 AIDP29/36 (80.5)
 AMAN1/36 (2.8)
 AMSAN5/36 (13.9)
 Equivocal1/36 (2.8)
 CSF
 Not done6 (14.3)
 Normal8/36 (22.2)
 Albuminocytological dissociation28/36 (77.8)
 RT-PCR for SARS-CoV-2 negative25/25(100)
Antiganglioside antibodies
 Not done20 (47.6)
 Negative21/22 (95.5)
 GD1b (1gG)1/22 (4.5)
MRI
 Not done17 (41.5)
 Normal/not contributory16/25 (64.0)
 Cranial nerves enhancement5/25 (20.0)
 Roots/plexus enhancement5/25 (20.0)
 Brainstem and spine leptomeningeal enhancement1/25 (4.0)
Brighton criteria
 Not applicable7 (16.7)
 Level 119/35 (54.3)
 Level 214/35 (40.0)
 Level 32/35 (5.7)
Respiratory failure14 (33.3)
 Non-invasive ventilation2/14 (14.3)
 Invasive ventilation12/14 (85.7)
ICU admission17 (40.5)
Immunotherapy
 Not reported1 (2.4)
 Not done1 (2.4)
 IVIG35 (83.3)
 PE2 (4.8)
 IVIG and PE2 (4.8)
 Oral steroids1 (2.4)
Follow-up
 Not reported5 (12.0)
 Death1/37 (2.7)
 No improvement4/37 (10.8)
 Minimal/slight improvement7/37 (18.9)
 Definite improvement16/37 (43.2)
 Recovery7/37 (18.9)
  • AIDP, acute inflammatory demyelinating polyneuropathy; AMAN, acute motor axonal neuropathy; AMSAN, acute motor and sensory axonal neuropathy; CSF, cerebrospinal fluid examination; ICU, intensive care unit; IVIG, intravenous immunoglobulin; LLs, lower limbs; PE, plasma exchange; RT-PCR, reverse transcriptase PCR.